Polygenic Risk Scoring: An Epidemiologist’s Perspective
![The Accad & Koka Report](https://cdn.mises.org/styles/responsive_4_3_650w/s3/static-page/img/TheAccad%26KokaReport_750x516_v2_20181129.png.webp?itok=xcYJg8wj 650w,https://cdn.mises.org/styles/responsive_4_3_870w/s3/static-page/img/TheAccad%26KokaReport_750x516_v2_20181129.png.webp?itok=4tA-5gSL 870w,https://cdn.mises.org/styles/responsive_4_3_1090w/s3/static-page/img/TheAccad%26KokaReport_750x516_v2_20181129.png.webp?itok=HI4f-Rqa 1090w,https://cdn.mises.org/styles/responsive_4_3_1310w/s3/static-page/img/TheAccad%26KokaReport_750x516_v2_20181129.png.webp?itok=gL8uwCsq 1310w,https://cdn.mises.org/styles/responsive_4_3_1530w/s3/static-page/img/TheAccad%26KokaReport_750x516_v2_20181129.png.webp?itok=H1UV-41Y 1530w)
Has cardiovascular genetics come of age? Are “polygenic risk scores” ready to inform us in clinically meaningful ways? In the final analysis, who or what are epidemiological data informing? Our guest is A. Cecile Janssens, PhD, Professor of Translational Epidemiology at the Rollins school of Public Health at Emory university in Atlanta, Georgia.
Professor Janssens’ research concerns the translation of genomics research to applications in clinical and public health practice and focuses on the genetic prediction of common diseases such as diabetes, cardiovascular disease and cancer. She also studies how the predictive ability and utility of genetic testing can best be measured.